Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Hospira

Related HSP
Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals Inc
Top 4 NYSE Stocks In The Drugs-Generic Industry With The Highest Profit Margin

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Hospira (NYSE: HSP).

Morgan Stanley noted, “November IMS sales were $118 MM, down 4% Y/Y and down 2% MoM vs. down 6% Y/Y and up 2% MoM in October suggesting stability in US SIP. Core business weekly average sales were +4.6% M/M versus +1.1% in October consistent with some progress in 4Q. However, stock performance remains more tied to 1H13 Rocky Mount re-inspection and device remediation progress.”

Hospira closed on Friday at $30.69.

Latest Ratings for HSP

DateFirmActionFromTo
Dec 2014BarclaysMaintainsEqual-weight
Nov 2014JP MorganMaintainsNeutral
Nov 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for HSP
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HSP)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional